Fig. 6. In vitro and in vivo inhibitory activities of ICA135 against CV-A10 infection.

a Inhibitory effect of ICA135 on CV-A10 infection of RD cells. 50 µl of CV-A10/S0148b virus containing 100 TCID50 was mixed with 50 µl of compound dilutions, and incubated at 37 °C for 1 h. The mixtures were added to 2 × 10⁴ RD cells to allow infection at 37 °C for 6 h. Then, the mixtures were replaced with fresh medium and the plates were incubated at 37 °C for 24 h. The cells and medium were harvested and subjected to realtime PCR assay. Each experiment was performed at least three times. b, c In vivo inhibitory effect of ICA135. Groups of 7-day-old ICR mice (n = 14 or 15) were inoculated intraperitoneally (i.p.) with 8 × 10⁴ TCID50 of CV-A10/S0148b in the absence or presence of 50 mg/kg body weight of ICA135. Then the mice were monitored daily for survival (b) and clinical signs (c) for a period of 14 days. Clinical scores were graded as follows: 0, healthy; 1, reduced mobility; 2, limb weakness; 3, paralysis; 4, death. Survival curves for the control and treatment groups were compared by Log-rank test using GraphPad Prism software. Mean clinical scores for the two groups were compared by two-way ANOVA test. Statistical significance was indicated as **P ≤ 0.01